Bibliographic information
GuidelineTherapeutics and COVID-19: living guideline, August 2025
Year of Publication2025
Issuing InstitutionWorld Health Organization
Recommendation
Maintained
We recommend not to use remdesivir for patients with non-severe COVID-19 at low risk of hospitalization
Recommended against
Strong
Notes and Remarks
- See Section 6 regarding identifying patients at low risk.
- The marginal benefits of remdesivir for patients at low risk of hospitalization (those expected to have a 0.5% risk of hospital admission) suggest most patients would not want to use this treatment.
- Given considerations regarding resources and equity, the GDG concluded that health care systems may reasonably not offer this drug to patients at low risk of hospitalization. Practical info Given the strong recommendation against using remdesivir for patients with non-severe COVID-19 at low risk of hospitalization, practical considerations were felt to be less relevant here.
Also Featured In
This recommendation also appears in the following guidelines:
Originally Developed
Guideline
Therapeutics and COVID-19: living guideline, 10 November 2023.
Year2023
InstitutionWorld Health Organization